What is Syros Pharmaceut's earnings per share (EPS)?

Syros Pharmaceut (SYRS) reported diluted earnings per share of -$5.81 for fiscal year 2023. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Syros Pharmaceut (SYRS) Financials

SYRS

FY2023 annual

Revenue $9.9M -33.2% YoY

Net Income -$164.6M -73.9% YoY

EPS (Diluted) -$5.81 YoY not available

Free Cash Flow -$110.0M +11.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2024, ended Sep 30, 2024 Reported Oct 31, 2024 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2024, filed Oct 31, 2024. Each column of the statement tables below links to the filing it was taken from.

Syros Pharmaceut (SYRS) reported $9.9M in revenue for fiscal year 2023, down 33.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SYRS FY2023 2026-08-30

Development spending, rather than product revenue, remains the dominant mechanic governing Syros's cash use and financing needs.

Across FY2022 and FY2023, research and development spending stayed nearly constant at $111.9M and $108.2M, respectively. Operating cash flow of -$123.1M and -$109.7M moved in parallel, indicating that cash consumption was chiefly tied to sustaining the development program rather than a temporary working-capital swing.

FY2023's liabilities reached $151.5M against only $16.7M of equity, leaving a much thinner capital cushion as the asset base contracted. The balance sheet therefore appears liquid in the short term, with a current ratio of 4.0x, but more dependent on liabilities structurally as debt-to-equity rose to 2.1x from 0.3x in FY2022.

Revenue fell to $9.9M in FY2023 while R&D remained at $108.2M, showing that development spending was largely disconnected from current commercial inflow. Reported cash, equivalents, and investments equaled 15.3 months of the latest annual operating outflow, while financing cash flow was $43.5M; this describes external funding alongside continued cash consumption, not internally self-financed operations.

Financial Health Signals

Financial health score not available

Syros Pharmaceut does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/8

Syros Pharmaceut passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Syros Pharmaceut reported a net loss of $164.6M while operations used $109.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Syros Pharmaceut reported an operating loss of $129.0M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$25.9M

YoY+24.0%

QoQ+4.5%

Syros Pharmaceut's EBITDA was -$25.9M in Q3 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.0% from the same quarter a year earlier. Against the prior quarter it is up 4.5%.

Net Income

-$6.4M

YoY+84.1%

QoQ+72.6%

Syros Pharmaceut reported -$6.4M in net income in Q3 2024. This represents an increase of 84.1% from the same quarter a year earlier. Against the prior quarter it is up 72.6%.

EPS (Diluted)

-$0.16

YoY+88.8%

QoQ+72.9%

Syros Pharmaceut earned -$0.16 per diluted share (EPS) in Q3 2024. This represents an increase of 88.8% from the same quarter a year earlier. Against the prior quarter it is up 72.9%.

Revenue

Not reported for Q3 2024.

Cash & Balance Sheet

Cash & Debt

$58.3M

YoY-48.1%

QoQ-26.2%

5Y CAGR+11.8%

Syros Pharmaceut held $58.3M in cash against $41.1M in long-term debt as of Q3 2024.

Shares Outstanding

27M

YoY+29.5%

QoQ0.0%

5Y CAGR-8.8%

Syros Pharmaceut had 27M shares outstanding in Q3 2024. This represents an increase of 29.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2024.

Dividends Per Share

Not reported for Q3 2024.

Margins & Returns

None of these metrics is reported for Q3 2024.

Capital Allocation

R&D Spending

$20.5M

YoY-27.4%

QoQ-6.5%

Syros Pharmaceut invested $20.5M in research and development in Q3 2024. This represents a decrease of 27.4% from the same quarter a year earlier. Against the prior quarter it is down 6.5%.

Share Buybacks

Not reported for Q3 2024.

Capital Expenditures

Not reported for Q3 2024.

SYRS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SYRS quarterly income statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$9.9M-33.2%	$14.9M-36.6%	$23.5M+55.6%	$15.1M+661.5%	$2.0M-3.3%	$2.0M+86.2%	$1.1M+247.3%	$317K	N/A	N/A
R&D Expenses	$88.6M	$108.2M-3.4%	$111.9M+12.1%	$99.9M+31.3%	$76.1M+30.6%	$58.2M+16.1%	$50.2M+19.8%	$41.9M+10.8%	$37.8M+54.9%	$24.4M+123.5%	$10.9M
SG&A Expenses	$23.3M	$28.3M-3.5%	$29.3M+27.2%	$23.0M+8.0%	$21.3M-0.7%	$21.5M+32.9%	$16.2M+16.4%	$13.9M+32.8%	$10.5M+82.6%	$5.7M+128.1%	$2.5M
Operating Income	-$111.7M	-$129.0M+5.1%	-$135.9M-36.7%	-$99.4M-20.8%	-$82.3M-5.9%	-$77.7M-20.9%	-$64.3M-17.6%	-$54.7M-14.0%	-$48.0M-60.8%	-$29.8M-122.0%	-$13.4M
EBITDA	N/A	-$126.7M+4.8%	-$133.2M-37.8%	-$96.7M-21.6%	-$79.5M-5.7%	-$75.2M-20.0%	-$62.7M-17.9%	-$53.2M-13.9%	-$46.7M-59.8%	-$29.2M-121.7%	-$13.2M
Interest Expense	$5.3M	$5.1M+24.0%	$4.1M+5.8%	$3.9M+118.0%	$1.8M+2388.9%	$72K+7100.0%	$1K	N/A	N/A	N/A	N/A
Income Tax	N/A	$1K-66.7%	$3K+200.0%	$1K-75.0%	$4K-85.7%	$28K+16.7%	$24K+242.9%	$7K+250.0%	$2K	N/A	N/A
Net Income	-$97.8M	-$164.6M-73.9%	-$94.7M-9.4%	-$86.6M-3.0%	-$84.0M-11.5%	-$75.4M-21.0%	-$62.3M-15.4%	-$54.0M-13.2%	-$47.7M-60.1%	-$29.8M-122.4%	-$13.4M
EPS (Basic)	N/A	-$5.81+22.4%	-$7.49+45.9%	-$13.84+24.0%	-$18.20	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$3.07	-$5.81	-$7.49	-$13.84+24.0%	-$18.20	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	28M	13M	6M+35.8%	5M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Revenue	N/A	N/A	N/A	$387K	$3.8M-3.3%	$2.8M-54.9%	$3.0M-46.0%	N/A
R&D Expenses	$20.5M-27.4%	$22.0M-25.9%	$24.7M-14.3%	$21.5M	$28.3M+9.8%	$29.6M-10.5%	$28.8M+14.3%	N/A
SG&A Expenses	$5.7M-27.2%	$5.5M-24.4%	$6.3M-15.4%	$5.9M	$7.8M-3.9%	$7.2M+4.0%	$7.4M+6.6%	N/A
Operating Income	-$26.2M+24.4%	-$27.4M+19.4%	-$30.9M+6.9%	-$27.1M	-$34.6M+12.2%	-$34.0M-0.7%	-$33.2M-24.6%	N/A
EBITDA	-$25.9M+24.0%	-$27.1M+18.8%	-$30.6M+6.1%	-$26.8M	-$34.0M+12.3%	-$33.4M-0.7%	-$32.6M-25.4%	N/A
Interest Expense	$1.3M+0.7%	$1.4M+8.1%	$1.3M+7.4%	$1.3M	$1.3M+24.0%	$1.3M+30.3%	$1.2M+24.7%	N/A
Net Income	-$6.4M+84.1%	-$23.3M+35.7%	-$3.7M+84.4%	-$64.4M	-$40.1M-32.7%	-$36.3M-5.2%	-$23.8M+5.4%	N/A
EPS (Basic)	-$0.16+88.8%	-$0.59+54.6%	-$0.10+88.2%	-$2.22-150.0%	-$1.43+55.5%	-$1.30+75.9%	-$0.85+78.7%	$4.44+217.5%
EPS (Diluted)	-$0.16+88.8%	-$0.59+54.6%	-$0.10+88.2%	-$2.22-150.0%	-$1.43	-$1.30	-$0.85	$4.44
Diluted Shares (Avg)	39M+40.5%	39M+40.7%	39M+40.0%	N/A	28M	28M	28M	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

SYRS Balance Sheet

SYRS quarterly balance sheet

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$168.2M-31.2%	$244.5M+33.6%	$182.9M-14.2%	$213.3M+42.2%	$150.0M+40.5%	$106.8M+36.0%	$78.5M-14.1%	$91.3M+109.3%	$43.6M	N/A
Current Assets	$145.0M-31.4%	$211.4M+54.8%	$136.6M-23.5%	$178.6M+55.9%	$114.5M+12.6%	$101.7M+39.1%	$73.2M-14.4%	$85.5M+134.6%	$36.4M	N/A
Cash & Equivalents	$139.5M-16.7%	$167.5M+81.4%	$92.3M-46.9%	$174.0M+319.8%	$41.4M-16.9%	$49.9M+54.9%	$32.2M-45.0%	$58.6M+63.2%	$35.9M-40.5%	$60.4M
Short-Term Investments	$0-100.0%	$34.8M-8.5%	$38.1M	$0-100.0%	$50.0M+0.4%	$49.8M+25.0%	$39.8M+59.3%	$25.0M	$0	$0
Accounts Receivable	N/A	N/A	N/A	$7K-100.0%	$20.0M	N/A	N/A	$867K	N/A	N/A
Long-Term Investments	$0	$0-100.0%	$13.0M	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$151.5M+29.8%	$116.8M+19.5%	$97.7M-20.4%	$122.7M+73.3%	$70.8M+151.2%	$28.2M+114.1%	$13.2M+22.8%	$10.7M-88.3%	$91.6M	N/A
Current Liabilities	$36.7M+19.2%	$30.8M-2.3%	$31.5M+10.1%	$28.6M+21.7%	$23.5M+20.4%	$19.5M+57.3%	$12.4M+29.7%	$9.6M+20.2%	$8.0M	N/A
Non-Current Liabilities	$114.8M+33.6%	$86.0M+29.8%	$66.2M-29.6%	$94.1M+99.0%	$47.3M+446.5%	$8.7M+1051.9%	$751K-34.9%	$1.2M-98.6%	$83.6M	N/A
Long-Term Debt	$34.6M-15.0%	$40.6M+1.0%	$40.3M+1.8%	$39.6M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.7M-87.0%	$127.7M+49.9%	$85.2M-5.9%	$90.6M+14.4%	$79.2M+0.8%	$78.6M+20.3%	$65.3M-19.0%	$80.6M+268.0%	-$48.0M-120.3%	-$21.8M
Retained Earnings	-$722.8M-29.5%	-$558.2M-20.4%	-$463.6M-23.0%	-$377.0M-28.7%	-$293.0M-34.7%	-$217.5M-40.1%	-$155.3M-53.3%	-$101.3M-89.2%	-$53.5M	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Total Assets	$85.0M-42.5%	$106.7M-41.0%	$134.7M-34.4%	$168.2M-31.2%	$147.8M-48.1%	$181.0M+43.4%	$205.3M+35.0%	$244.5M+33.6%
Current Assets	$63.9M-47.8%	$84.9M-44.4%	$112.2M-35.4%	$145.0M-31.4%	$122.5M-51.4%	$152.6M+66.0%	$173.6M+49.1%	$211.4M+54.8%
Cash & Equivalents	$58.3M-48.1%	$79.0M-31.6%	$83.5M-20.3%	$139.5M-16.7%	$112.2M-34.6%	$115.4M+95.5%	$104.8M+50.6%	$167.5M+81.4%
Short-Term Investments	$0	$0-100.0%	$24.8M-59.4%	$0-100.0%	$0-100.0%	$28.5M+4.8%	$61.0M+50.0%	$34.8M-8.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%
Total Liabilities	$96.1M-13.8%	$113.1M+4.9%	$119.7M+21.4%	$151.5M+29.8%	$111.5M-28.3%	$107.7M+13.2%	$98.6M+10.3%	$116.8M+19.5%
Current Liabilities	$28.4M0.0%	$24.5M-13.6%	$37.3M+58.4%	$36.7M+19.2%	$28.4M-26.1%	$28.4M-27.1%	$23.6M-14.6%	$30.8M-2.3%
Non-Current Liabilities	$67.7M-18.5%	$88.6M+11.6%	$82.4M+9.8%	$114.8M+33.6%	$83.1M-29.1%	$79.4M+41.0%	$75.0M+21.5%	$86.0M+29.8%
Long-Term Debt	$41.1M+4.3%	$40.9M0.0%	$29.7M-24.1%	$34.6M-15.0%	$39.4M-2.7%	$40.9M+20.5%	$39.1M+0.9%	$40.6M+1.0%
Total Equity	-$11.1M-130.6%	-$6.4M-108.7%	$15.1M-85.9%	$16.7M-87.0%	$36.3M-71.9%	$73.2M+136.1%	$106.8M+70.1%	$127.7M+49.9%
Retained Earnings	-$756.2M-14.9%	-$749.8M-21.3%	-$726.5M-24.8%	-$722.8M-29.5%	-$658.4M-19.0%	-$618.3M-18.2%	-$582.0M-19.1%	-$558.2M-20.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

SYRS Cash Flow Statement

SYRS quarterly cash flow statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$100.0M	-$109.7M+10.9%	-$123.1M-23.6%	-$99.5M-73.5%	-$57.4M+4.8%	-$60.3M-49.5%	-$40.3M+9.9%	-$44.7M-10.3%	-$40.5M-76.0%	-$23.0M-92.4%	-$12.0M
Depreciation & Amortization	N/A	$2.3M-16.8%	$2.7M-1.9%	$2.8M-0.6%	$2.8M+10.0%	$2.5M+57.2%	$1.6M+5.0%	$1.5M+20.0%	$1.3M+111.5%	$602K+133.3%	$258K
Stock-Based Compensation	N/A	$10.4M-8.6%	$11.4M+10.2%	$10.4M-5.3%	$10.9M+11.2%	$9.8M+48.9%	$6.6M+49.6%	$4.4M+4.4%	$4.2M+31.0%	$3.2M+245.0%	$937K
Capital Expenditures	N/A	$272K-78.1%	$1.2M-0.3%	$1.2M-62.7%	$3.3M-73.6%	$12.6M+813.2%	$1.4M+68.6%	$821K-64.6%	$2.3M+97.4%	$1.2M+485.1%	$201K
Free Cash Flow	N/A	-$110.0M+11.5%	-$124.3M-23.3%	-$100.8M-66.0%	-$60.7M+16.7%	-$72.9M-74.8%	-$41.7M+8.5%	-$45.5M-6.3%	-$42.9M-77.1%	-$24.2M-98.9%	-$12.2M
Investing Cash Flow	$1.9M	$37.3M-44.4%	$67.2M+227.6%	-$52.7M-212.8%	$46.7M+497.7%	-$11.7M-10.3%	-$10.6M+31.7%	-$15.6M+43.0%	-$27.3M-2225.0%	-$1.2M	N/A
Financing Cash Flow	$43.2M	$43.5M-66.8%	$131.0M+85.9%	$70.5M-50.7%	$143.0M+116.6%	$66.0M-4.5%	$69.1M+103.6%	$33.9M-62.5%	$90.6M+32674.5%	-$278K	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Operating Cash Flow	-$20.7M+35.1%	-$29.7M-32.5%	-$31.1M+15.7%	-$18.6M+40.3%	-$31.9M+11.0%	-$22.4M+14.5%	-$36.9M-22.9%	-$31.1M-35.3%
Depreciation & Amortization	$325K-46.9%	$331K-49.1%	$334K-47.6%	$352K-50.1%	$612K-7.1%	$650K-1.7%	$638K-6.3%	$705K-0.4%
Stock-Based Compensation	$1.6M-50.1%	$1.8M-35.9%	$2.1M-20.5%	N/A	$3.3M+10.2%	$2.8M+4.6%	$2.6M-7.6%	N/A
Capital Expenditures	N/A	N/A	N/A	$38K-94.4%	$0-100.0%	-$1K-99.1%	$235K+83.6%	$674K+175.1%
Free Cash Flow	N/A	N/A	N/A	-$18.6M+41.4%	-$31.9M+11.8%	-$22.4M+14.8%	-$37.1M-23.2%	-$31.8M-36.8%
Investing Cash Flow	$0-100.0%	$25.1M-23.9%	-$24.6M+4.3%	$1.5M-96.0%	$28.6M+362.5%	$32.9M+107.2%	-$25.7M-448.7%	$37.7M+15496.3%
Financing Cash Flow	$0+100.0%	$41K-70.7%	-$265K-400.0%	$43.4M+505.3%	-$5K-100.0%	$140K+162.8%	-$53K+43.0%	-$10.7M-11249.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SYRS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SYRS quarterly financial ratios

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Margin	-1298.2%	-913.1%	-423.3%	-545.3%	-3922.4%	-3136.4%	-4966.9%	-15130.3%	N/A	N/A
Net Margin	-1656.3%	-636.1%	-368.5%	-556.8%	-3804.2%	-3039.0%	-4904.6%	-15047.3%	N/A	N/A
Return on Equity	-987.7%-913.6pp	-74.1%+27.5pp	-101.6%-8.8pp	-92.8%+2.4pp	-95.2%-15.9pp	-79.3%+3.4pp	-82.7%-23.5pp	-59.2%	N/A	N/A
Return on Assets	-97.9%-59.1pp	-38.7%+8.6pp	-47.3%-7.9pp	-39.4%+10.9pp	-50.3%+8.1pp	-58.4%+10.4pp	-68.8%-16.6pp	-52.2%+16.1pp	-68.3%	N/A
Current Ratio	3.95-2.9x	6.87+2.5x	4.33-1.9x	6.24+1.4x	4.87-0.3x	5.21-0.7x	5.89-3.0x	8.94+4.4x	4.58	N/A
Debt-to-Equity	2.07+1.8x	0.32-0.2x	0.470.0x	0.44-0.5x	0.89+0.5x	0.36+0.2x	0.20+0.1x	0.13	N/A	N/A
Asset Turnover	0.060.0x	0.06-0.1x	0.13+0.1x	0.07+0.1x	0.010.0x	0.020.0x	0.010.0x	0.00	N/A	N/A
FCF Margin	-1106.9%	-835.4%	-429.1%	-402.2%	-3677.6%	-2034.1%	-4137.1%	-13519.9%	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Operating Margin	N/A	N/A	N/A	-7012.9%	-920.7%	-1200.1%	-1124.3%	N/A
Net Margin	N/A	N/A	N/A	-16636.7%	-1067.1%	-1279.8%	-805.3%	N/A
Return on Equity	N/A	N/A	-24.6%-2.3pp	-386.4%	-110.6%-87.2pp	-49.5%+61.6pp	-22.3%+17.8pp	N/A
Return on Assets	-7.5%+19.6pp	-21.9%-1.8pp	-2.8%+8.8pp	-38.3%	-27.2%-16.5pp	-20.0%+7.3pp	-11.6%+4.9pp	N/A
Current Ratio	2.25-2.1x	3.46-1.9x	3.01-4.4x	3.95-2.9x	4.31-2.3x	5.38+3.0x	7.37+3.2x	6.87+2.5x
Debt-to-Equity	N/A	N/A	1.97+1.6x	2.07+1.8x	1.09+0.8x	0.56-0.5x	0.37-0.3x	0.32-0.2x
Asset Turnover	N/A	N/A	N/A	0.00	0.030.0x	0.020.0x	0.010.0x	N/A
FCF Margin	N/A	N/A	N/A	-4806.2%	-846.8%	-790.2%	-1257.1%	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Syros Pharmaceut SYRS	FY2023	$9.9M	-$164.6M	N/A	N/A	—
Aridis Pharmaceuticals Inc ARDS	FY2022	$3.1M	-$30.4M	N/A	$4K	—
Endonovo Therape ENDV	FY2022	$135K	N/A	N/A	$145K	—

Where Syros Pharmaceut Ranks

Frequently Asked Questions

What is Syros Pharmaceut's annual revenue?

Syros Pharmaceut (SYRS) reported $9.9M in total revenue for fiscal year 2023. This represents a -33.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Syros Pharmaceut's revenue growing?

Syros Pharmaceut (SYRS) revenue declined by 33.2% year-over-year, from $14.9M to $9.9M in fiscal year 2023.

Is Syros Pharmaceut profitable?

No, Syros Pharmaceut (SYRS) reported a net income of -$164.6M in fiscal year 2023.

What is Syros Pharmaceut's EBITDA?

Syros Pharmaceut (SYRS) had EBITDA of -$126.7M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Syros Pharmaceut have?

As of fiscal year 2023, Syros Pharmaceut (SYRS) had $139.5M in cash and equivalents against $34.6M in long-term debt.

What is Syros Pharmaceut's return on equity (ROE)?

Syros Pharmaceut (SYRS) has a return on equity of -987.7% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.

What is Syros Pharmaceut's free cash flow?

Syros Pharmaceut (SYRS) recorded an outflow of $110.0M in free cash flow during fiscal year 2023. This represents a 11.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Syros Pharmaceut's operating cash flow?

Syros Pharmaceut (SYRS) recorded an outflow of $109.7M in operating cash flow during fiscal year 2023, representing cash used by core business activities.

What are Syros Pharmaceut's total assets?

Syros Pharmaceut (SYRS) had $168.2M in total assets as of fiscal year 2023, including both current and long-term assets.

What are Syros Pharmaceut's capital expenditures?

Syros Pharmaceut (SYRS) invested $272K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

How much does Syros Pharmaceut spend on research and development?

Syros Pharmaceut (SYRS) invested $108.2M in research and development during fiscal year 2023.

How many shares does Syros Pharmaceut have outstanding?

Syros Pharmaceut (SYRS) had 26M shares outstanding as of fiscal year 2023.

What is Syros Pharmaceut's current ratio?

Syros Pharmaceut (SYRS) had a current ratio of 3.95 as of fiscal year 2023, which is generally considered healthy.

What is Syros Pharmaceut's debt-to-equity ratio?

Syros Pharmaceut (SYRS) had a debt-to-equity ratio of 2.07 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Syros Pharmaceut's return on assets (ROA)?

Syros Pharmaceut (SYRS) had a return on assets of -97.9% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

How does Syros Pharmaceut's liquidity compare with its operating cash outflow?

At the end of fiscal year 2023, Syros Pharmaceut (SYRS) held $139.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $109.7M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Syros Pharmaceut's Piotroski F-Score?

Syros Pharmaceut (SYRS) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Syros Pharmaceut's earnings high quality?

Syros Pharmaceut (SYRS) reported a net loss of $164.6M while operations used $109.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Syros Pharmaceut cover its interest payments?

Syros Pharmaceut (SYRS) reported an operating loss of $129.0M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.